SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
BioMedReports: FDA Calendar Updates
WPI
|
|
|
+7.91%
in
118 days
<> Below is a summary of updates to the BioMedReports.com FDA Calendar , which includes a database of 260 entries as of 7/15/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-stage clini...
|
Bullish on WPI ...
WPI
|
|
|
+20.38%
in
188 days
Watson Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, marketing, sale, and distribution of generic and brand pharmaceutical products primarily in the United States. The company?s products are used in various therapeutic areas, including central nervous system, hormones and synthetic substitutes, cardiovascular, nephrology, gastrointestinal, and other areas. It operates in three segments: Generic, Brand, and Distribution. The Generic segment manufactures and sells generic products for various therapeutic classes comprising anti-depressant,...
|
FDA, Clinical Trial Calendar Updates: Genzyme, Isis, Osiris, Roche, Watson
WPI
|
|
|
+10.82%
in
84 days
(closed on 07/15/09)
<> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions to the FDA for complete r...
|
Big Pharma Goes Generic
WPI
|
|
|
+0.57%
in
55 days
(closed on 04/22/09)
<> <> <> <> <> <>  Sanofi-Aventis (SNY) is now the 11 th largest generic drug maker in the world following its successful acquisition of Czech generic drug company Zentiva. As $70B in brand drug patents are set to expire through 2012, big pharma companies are hedging their bets through generic drug divisions, including Pfizer (PFE) - Greenstone, Novartis (NVS) - Sandoz, and the recently announced Merck (MRK) BioVent...
|
A 130/30 Pharma Trade
WPI
|
|
|
+1.21%
in
6 days
(closed on 02/26/09)
By Mike Havrilla on 2/20/09 ETF Innovators The tables at my website link below include 12 U.S. listed companies from the ETF Innovators Global Generic Drug Index along with seven brand drug companies, which are ranked in descending order based on their patent expiration exposure through the end of 2011 as a percentage of total trailing 12-month revenue. <> Investors who are bullish on the generic drug industry may consider implementing a 130/30 pharma trade by shorting any/all...
|
From the Blogosphere
Watson Pharma Beats by a Penny – Analyst Blog
|
|
|
Watson Pharmaceuticals, Inc. (WPI) reported third quarter earnings of 66 cents per share, a cent above the Zacks Consensus Estimate. Margin improvements resulting from operating efficiencies achieved through the company’s Global Supply Chain Initiative and contributions from new products helped increase earnings by 40% from the year-ago period. Revenues increased 3% to $662.1 million.
The Generic product division posted sales of $392.3 million, up 11%. The increase was driven by contributions from new products like the generic version of AstraZeneca’s (AZN) Toprol XL (potassium-chloride ...
|
Inflation rate up 10.66pc during first quarter
|
|
|
ISLAMABAD , Pakistan – Inflation rate up 10.66pc during first quarter, Inflation remains in double digits in the first quarter (July-September) of current fiscal year 2009-10 despite State Bank of Pakistan (SBP) pursued tight monetary policy in the aforementioned period to arrest it. The SBP in its latest monetary policy has maintained mark up rate at 13 percent to control the soaring inflation, which enhanced by 10.66 percent in July-September 2009. <>The government in the current federal budget targeted to bring inflation down to a single digit in the year 2009. The economists believed that...
|
Mylan: Generic Drugmaker with a Strong Portfolio
<>Mylan Pharmaceuticals (MYL) keeps coming up on my radar so I would like to take the time to analyze the stock and give some recommendations on it. Mylan is approaching its 52 week high so is it a buy or not? In October 2008, they reached a 52 week low of 5.75 and today is trading at 14.88. So that old adage of Buy Low-Sell High is coming into play. In these economic times many rules of trading are finding exceptions to that rule. Mylan's Financial picture can be found on Google Finance here. I see a good exception to Mylan's future, and see the company's stock rising based on FDA approvals ...
|
Watson wants a bulls-eye with the Arrow deal
Notable Mergers and Acquisitions of the Day 6/17: WPI, DNBK/BNV, AGU/CF
|
<> <>Watson Pharmaceuticals, Inc. (NYSE: WPI) entered into a definitive agreement to acquire privately held Arrow Group for $1.75 billion in cash and stock.The combination of Watson and Arrow will result in a global pharmaceutical company with over $3 billion in revenue, commercial operations in over 20 countries, and a robust product portfolio and pipeline.Watson expects the transaction to close in the second half of 2009, and be accretive to cash earnings per share in 2010 before synergies.Under the terms of the agreement, Watson will acquire Arrow for cash and stock consideration of $1.75 bi...
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
Visit streetinsider.com
Be the first to start a discussion and earn 2 points.
More Resources
|
About Watson Pharmaceuticals Inc.
- Answers.com
While M&A activity has been mostly lackluster, this has not been the case in the pharma industry. The major players are trying to reposition themselves for changes in regulations, as well as patent expirations of mega drugs.
